Sarcoma de Kaposi · línea 1 · Ninguno
Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.
Registro de base de conocimiento para la auditoría. Contenido clínico provisional: esto no es una prescripción. Un oncólogo debe verificar fuentes originales, aplicabilidad y estado de revisión.
Fuente YAML: registro completo
| Línea de tratamiento | 1 |
|---|---|
| Track | local_therapy |
| Régimen vinculado | None |
| ID | IND-KAPOSI-1L-CLASSIC-LOCAL-OBSERVATION |
|---|---|
| Tipo | Indicación |
| Situación | reviewed 2026-07-11 | pending_clinical_signoff |
| Enfermedades | DIS-KAPOSI |
| Fuentes | SRC-IARC-MONO-100B-2012 SRC-NCCN-SKIN-2025 |
Notas
STUB -- new TREATMENT-intent Indication for DIS-KAPOSI (v0.3 continuation), covering classic and endemic forms. Deliberately has `recommended_regimen: null` -- the disease narrative specifies only "local therapy or observation" without a preferred modality or dose, and CHARTER §8.3 prohibits inventing one; local-therapy modality selection is left to MDT/dermatology-oncology discretion pending future authoring of a dedicated local-therapy Regimen/Surgery/ RadiationCourse entity if the clinical co-leads want one formalized. INDEPENDENT REVIEW CORRECTION (2026-07-11): an earlier draft cited SRC-NCCN-SKIN-2025 with position "supports" and populated the `known_controversies[].positions[].sources` with the same id. That source documents only basal-cell/squamous-cell skin cancer (confirmed by direct inspection of its own KB record), not classic/ endemic Kaposi management -- downgraded the top-level citation to "context" and removed it from the controversy positions (no verifiable source for either side of that controversy exists in this KB, so left empty rather than fabricated). Pending two-Clinical- Co-Lead signoff (CHARTER §6.1 -- dev-mode-exempted; safe to merge as draft content, NOT...
Utilizado por
Algoritmos
ALGO-KAPOSI-1L- ALGO-KAPOSI-1L
Enfermedad
DIS-KAPOSI- Sarcoma Kaposi